<DOC>
	<DOCNO>NCT02611752</DOCNO>
	<brief_summary>Multi-site , randomize , double-blind , repeat-dose Phase 2 study evaluate degree duration action multiple dos CAM2038 block effect hydromorphone patient moderate severe opioid use disorder .</brief_summary>
	<brief_title>A Multiple Dose Opioid Challenge Study</brief_title>
	<detailed_description>This multi-site , randomize , double-blind , repeat-dose Phase 2 study evaluate degree duration action multiple dos CAM2038 q1w block effect mu opioid agonist ( hydromorphone ) patient moderate severe opioid use disorder . The study involve 4 phase : Screening , Qualification , Treatment , Follow-up . The study enroll sufficient number subject ensure least 48 subject complete study ( 24 subject per group least 16 female total ) . Replacement subject may add discretion sponsor agreement investigator .</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>1 . Subjects diagnosis moderate severe opioid use disorder ( Diagnostic Statistical Manual Mental Disorders Fifth Edition [ DSMV ] ) 2 . Selfreported opioiduse minimum 21 day 30 day prior Screening 3 . Positive urine drug screen ( UDS ) opioids Screening checkin . If UDS positive , subject must present physical sign withdrawal , determine Investigator . 4 . Female subject childbearing potential must willing use reliable method contraception entire study ( Screening Visit FollowUp phone call ) 5 . Female subject nonchildbearing potential surgically sterile ( i.e. , undergone complete hysterectomy , bilateral oophorectomy , tubal ligation ) menopausal state ( least 1 year without menses ) , confirm FSH level . 6 . Male subject female partner childbearing potential must agree use reliable method contraception Screening Visit least 3 month last dose study drug . Male subject must also agree donate sperm study least 3 month last dose study drug . 1 . Opioid dependent subject actively seek treatment moderate severe opioid use disorder . 2 . Subjects positive urine drug screen buprenorphine , alcohol , barbiturate , benzodiazepine methadone day check CRU breath alcohol urine alcohol test . 3 . Aspartate aminotransferase level &gt; 3 X upper limit normal , alanine aminotransferase level &gt; 3 X upper limit normal , total bilirubin &gt; 1.5 X upper limit normal , creatinine &gt; 1.5 X upper limit normal Screening laboratory assessment inpatient checkin , clinically significant laboratory abnormality , opinion Investigator may prevent subject safely participate study . 4 . Any clinically significant abnormality basis medical history , vital sign , physical examination , 12Lead electrocardiogram ( QTcF ≥450 msec male ≥470 msec female ) , laboratory evaluation ( include hematology , clinical chemistry , urinalysis , serology ) Screening , opinion Investigator . 5 . Significant symptom , medical condition , circumstance , opinion Investigator , would preclude compliance protocol , adequate cooperation study obtain informed consent , may prevent subject safely participate study ( include , limited , risk describe precaution , warning , contraindication current version Investigator 's Brochure CAM2038 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>